Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
R. Scott Greer
AddedMar 31, 2024
UpdatedMay 31, 2026
R. Scott Greer

R. Scott Greer

Founder, Numenor Ventures

Crunchbase

R. Scott Greer's Career

Numenor Ventures
Numenor Ventures

Santa Barbara, CA, US

Founder
Nektar Therapeutics
Nektar Therapeutics

San Francisco, CA, US

Board Member· Board
Acologix
Acologix

Hayward, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

R. Scott Greer's Career

Numenor Ventures
Numenor Ventures
Investment FirmInvestment Firm52002Santa Barbara, CA, US
Founder
Nektar Therapeutics
Nektar Therapeutics
Public$1.2B2161990San Francisco, CA, US
Board Member· Board

Leadership at Nektar Therapeutics

Rob ChessRob ChessBoard Member
Howard RobinHoward RobinBoard Member
John S. PattonJohn S. PattonFounder
Roy WhitfieldRoy WhitfieldBoard Member

Similar to Nektar Therapeutics

NKT TherapeuticsNKT TherapeuticsWaltham, MA, USTherapeuticsest. 2008NKT TherapeuticsWaltham, MA, US · est. 2008

NKT Therapeutics: A US-based biotech firm dedicated to developing treatments for cancer and serious diseases.

Series A · $12M8
NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
Neurona TherapeuticsNeurona TherapeuticsSouth San Francisco, CA, USCell Therapiesest. 2008Neurona TherapeuticsSouth San Francisco, CA, US · est. 2008

Neurona Therapeutics: Leading provider of cell-based medicines for neurological disorders.

Series A · $200.3M58
Nerx BiosciencesNerx BiosciencesIndianapolis, IN, USCancer Therapeuticsest. 2009Nerx BiosciencesIndianapolis, IN, US · est. 2009

US-based NĒRx BioSciences Inc, founded in 2009, specializes in discovering and developing targeted cancer therapeutics.

Seed · $500k11
Acologix
Acologix
Public$70M371992Hayward, CA, US
Board Member· Board

Leadership at Acologix

Thomas E SmartThomas E SmartBoard Member
Yoshinari KumagaiYoshinari KumagaiBoard Member
Dr Daniel F HothDr Daniel F HothBoard Member

R. Scott Greer's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to R. Scott Greer

Nick NaclerioNick NaclerioFounder · Illumina VenturesJohn BellJohn BellFounder · The Wellcome Trust Centre for Human GeneticsMitch SayareMitch SayareBoard Member · Isabella ProductsSteve GillisSteve GillisBoard Member · TakedaCaley CasteleinCaley CasteleinFounder · Kearny Venture PartnersAlbert FriedbergAlbert FriedbergBoard Member · Vaccinex